Literature DB >> 32386119

Whole-body magnetic resonance imaging as surveillance for subsequent malignancies in preadolescent, adolescent, and young adult survivors of germline retinoblastoma: An update.

Danielle Novetsky Friedman1,2, Meier Hsu1, Chaya S Moskowitz1,2, Jasmine H Francis1, Eric Lis1, Megan Harlan Fleischut1, Kevin C Oeffinger3, Michael Walsh1,2, Emily S Tonorezos1,2, Charles A Sklar1,2, David H Abramson1,2, Ira J Dunkel1,2.   

Abstract

BACKGROUND: Germline retinoblastoma (Rb) survivors are at lifelong risk for developing subsequent malignancies (SMNs). Optimal surveillance modalities are needed to detect SMN at an early stage in this high-risk cohort. We investigated the use of rapid whole-body magnetic resonance imaging (WB-MRI) as a noninvasive screening modality in this cohort. PROCEDURE: WB-MRI was performed in asymptomatic preadolescent, adolescent, or young adult survivors of germline Rb from February 1, 2008 to December 31, 2018 at a tertiary cancer center. We calculated sensitivity and specificity of WB-MRI and rate of false-positive findings requiring additional evaluation.
RESULTS: Overall, 110 WB-MRI were performed in 47 germline Rb survivors (51% female; median age at initial WB-MRI: 15.5 years [range 8-25.3]). Patients received 1-10 annual WB-MRI examinations (median: two). Thirteen patients had an abnormal WB-MRI; three findings were deemed to be likely benign and were not evaluated further. Ten patients required dedicated imaging and three required biopsy; two patients were diagnosed with localized high-grade osteosarcoma, while the other eight had benign findings. One patient was diagnosed with secondary osteosarcoma 3 months after normal WB-MRI. In total, there were 96 true negatives, 11 false positives, two true positives, and one false negative. The sensitivity of WB-MRI in this cohort was 66.7% (95% confidence interval [CI], 14.2-96.0) and the specificity was 89.7% (95% CI, 83.6-93.7).
CONCLUSIONS: Based on our 10-year experience, surveillance WB-MRI appears to have limited utility as a surveillance modality for SMN in germline Rb survivors. Alternate screening modalities should be investigated.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  retinoblastoma; second cancers; surveillance; survivorship; whole-body MRI

Mesh:

Year:  2020        PMID: 32386119      PMCID: PMC8177753          DOI: 10.1002/pbc.28389

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  17 in total

1.  Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.

Authors:  Mandy L Ballinger; Ana Best; Phuong L Mai; Payal P Khincha; Jennifer T Loud; June A Peters; Maria Isabel Achatz; Rubens Chojniak; Alexandre Balieiro da Costa; Karina Miranda Santiago; Judy Garber; Allison F O'Neill; Rosalind A Eeles; D Gareth Evans; Eveline Bleiker; Gabe S Sonke; Marielle Ruijs; Claudette Loo; Joshua Schiffman; Anne Naumer; Wendy Kohlmann; Louise C Strong; Jasmina Bojadzieva; David Malkin; Surya P Rednam; Elena M Stoffel; Erika Koeppe; Jeffrey N Weitzel; Thomas P Slavin; Bita Nehoray; Mark Robson; Michael Walsh; Lorenzo Manelli; Anita Villani; David M Thomas; Sharon A Savage
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

2.  Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma.

Authors:  Ruth A Kleinerman; Margaret A Tucker; David H Abramson; Johanna M Seddon; Robert E Tarone; Joseph F Fraumeni
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

3.  Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study.

Authors:  Danielle Novetsky Friedman; Eric Lis; Charles A Sklar; Kevin C Oeffinger; Marina Reppucci; Megan Harlan Fleischut; Jasmine H Francis; Brian Marr; David H Abramson; Ira J Dunkel
Journal:  Pediatr Blood Cancer       Date:  2013-11-01       Impact factor: 3.167

4.  Second primary osteosarcomas in patients with retinoblastoma.

Authors:  Tomohiro Fujiwara; Miyuki Fujiwara; Kunihiko Numoto; Koichi Ogura; Akihiko Yoshida; Tsukasa Yonemoto; Shigenobu Suzuki; Akira Kawai
Journal:  Jpn J Clin Oncol       Date:  2015-10-04       Impact factor: 3.019

5.  Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience.

Authors:  I J Dunkel; W L Gerald; N S Rosenfield; E W Strong; D H Abramson; F Ghavimi
Journal:  Med Pediatr Oncol       Date:  1998-01

6.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.

Authors:  Anita Villani; Uri Tabori; Joshua Schiffman; Adam Shlien; Joseph Beyene; Harriet Druker; Ana Novokmet; Jonathan Finlay; David Malkin
Journal:  Lancet Oncol       Date:  2011-05-19       Impact factor: 41.316

7.  Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?

Authors:  Kate A McBride; Mandy L Ballinger; Timothy E Schlub; Mary-Anne Young; Martin H N Tattersall; Judy Kirk; Ros Eeles; Emma Killick; Leslie G Walker; Sue Shanley; David M Thomas; Gillian Mitchell
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

8.  Cause-specific mortality in long-term survivors of retinoblastoma.

Authors:  Chu-Ling Yu; Margaret A Tucker; David H Abramson; Kyoji Furukawa; Johanna M Seddon; Marilyn Stovall; Joseph F Fraumeni; Ruth A Kleinerman
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 9.  Retinoblastoma and Neuroblastoma Predisposition and Surveillance.

Authors:  Junne Kamihara; Franck Bourdeaut; William D Foulkes; Jan J Molenaar; Yaël P Mossé; Akira Nakagawara; Andreu Parareda; Sarah R Scollon; Kami Wolfe Schneider; Alison H Skalet; Lisa J States; Michael F Walsh; Lisa R Diller; Garrett M Brodeur
Journal:  Clin Cancer Res       Date:  2017-07-01       Impact factor: 12.531

10.  Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.

Authors:  Sibel Saya; Emma Killick; Sarah Thomas; Natalie Taylor; Elizabeth K Bancroft; Jeanette Rothwell; Sarah Benafif; Alexander Dias; Christos Mikropoulos; Jenny Pope; Anthony Chamberlain; Ranga Gunapala; Louise Izatt; Lucy Side; Lisa Walker; Susan Tomkins; Jackie Cook; Julian Barwell; Vicki Wiles; Lauren Limb; Diana Eccles; Martin O Leach; Susan Shanley; Fiona J Gilbert; Helen Hanson; David Gallagher; Bala Rajashanker; Richard W Whitehouse; Dow-Mu Koh; S Aslam Sohaib; D Gareth Evans; Rosalind A Eeles
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

View more
  6 in total

Review 1.  Improving protocols for whole-body magnetic resonance imaging: oncological and inflammatory applications.

Authors:  Mareen S Kraus; Ayat A Yousef; Sandra L Cote; Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2022-08-19

2.  Cell Free DNA (cfDNA) in the Blood of Retinoblastoma Patients The Robert M. Ellsworth Lecture.

Authors:  David H Abramson
Journal:  Ophthalmic Genet       Date:  2022-04-05       Impact factor: 1.274

3.  Living with heritable retinoblastoma and the perceived role of regular follow-up at a retinoblastoma survivorship clinic: 'That is exactly what I have been missing'.

Authors:  Pernille Axel Gregersen; Mikkel Funding; Jan Alsner; Maja H Olsen; Jens Overgaard; Steen F Urbak; Sandra E Staffieri; Stina Lou
Journal:  BMJ Open Ophthalmol       Date:  2021-09-12

Review 4.  Screening of cancer predisposition syndromes.

Authors:  Haifa Al-Sarhani; Ravi V Gottumukkala; Angelo Don S Grasparil; Eric L Tung; Michael S Gee; Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2021-04-01

5.  Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013.

Authors:  Pernille A Gregersen; Maja H Olsen; Steen F Urbak; Mikkel Funding; Susanne O Dalton; Jens Overgaard; Jan Alsner
Journal:  JAMA Netw Open       Date:  2020-10-01

Review 6.  Whole-body magnetic resonance imaging (WB-MRI) for cancer screening: recommendations for use.

Authors:  Giuseppe Petralia; Fabio Zugni; Paul E Summers; Alberto Colombo; Paola Pricolo; Luigi Grazioli; Stefano Colagrande; Andrea Giovagnoni; Anwar R Padhani
Journal:  Radiol Med       Date:  2021-08-02       Impact factor: 3.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.